INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris F-75014, France; Paris Descartes University, Paris, France.
INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris F-75014, France; Univ. Paris-Sud, Université Paris-Saclay, F-92296 Châtenay-Malabry, France.
Environ Int. 2018 Apr;113:325-334. doi: 10.1016/j.envint.2018.01.004. Epub 2018 Feb 3.
Prenatal acrylamide exposure has been negatively associated with fetal growth but the association with child growth is unknown.
We studied the association between prenatal acrylamide exposure and child postnatal growth up to 8 years in the Norwegian Mother and Child Cohort Study (MoBa).
In 51,952 mother-child pairs from MoBa, acrylamide intake during pregnancy was estimated by combining maternal food intake with food concentrations of acrylamide. Mothers reported their child's weight and length/height up to 11 times between 6 weeks and 8 years. Weight and height growth trajectories were modelled using Jenss-Bayley's growth model. Logistic regression models were used to study the association with overweight/obese status at 3, 5 and 8 years, as identified using the International Obesity Task Force cut-offs. Linear mixed-effect models were used to explore associations with overall growth.
At 3 years, the adjusted odds ratios (95% Confidence Intervals (CI)) of being overweight/obese were 1.10 (1.02, 1.20), 1.12 (1.04, 1.22) and 1.21 (1.11, 1.31) by increasing prenatal acrylamide exposure quartile. Similar dose-response associations were found at 5 and 8 years. Acrylamide intake during pregnancy was associated with higher weight growth velocity in childhood. Children exposed at the highest level had 22 g (95% CI: 8, 37), 57 g (95% CI: 32, 81), and 194 g (95% CI: 110, 278) higher weight at 0.5, 2, and 8 years, respectively, compared to their low exposed peers.
Children prenatally exposed to acrylamide in the highest quartile experienced a moderate increase in weight growth velocity during early childhood that resulted in a moderately increased prevalence of overweight/obesity compared to peers in the lowest quartile. Our study is the first to link prenatal acrylamide exposure and postnatal growth.
产前丙烯酰胺暴露与胎儿生长呈负相关，但与儿童生长的关系尚不清楚。
我们在挪威母亲和儿童队列研究（MoBa）中研究了产前丙烯酰胺暴露与儿童产后 8 年内的生长发育之间的关系。
在 MoBa 的 51952 对母婴中，通过结合母体的食物摄入量和食物中丙烯酰胺的浓度来估计怀孕期间丙烯酰胺的摄入量。母亲在 6 周至 8 岁期间报告了孩子的体重和身高/长度 11 次。使用 Jenss-Bayley 生长模型对体重和身高增长轨迹进行建模。使用 logistic 回归模型研究了超重/肥胖与 3、5 和 8 岁时的关系，超重/肥胖的定义是使用国际肥胖问题工作组的切点。线性混合效应模型用于探索与整体生长的关系。
在 3 岁时，超重/肥胖的调整比值比（95%置信区间（CI））分别为 1.10（1.02，1.20）、1.12（1.04，1.22）和 1.21（1.11，1.31），按产前丙烯酰胺暴露四分位的增加而增加。在 5 岁和 8 岁时也发现了类似的剂量反应关系。怀孕期间丙烯酰胺的摄入量与儿童期体重增长速度有关。暴露于最高水平的儿童在 0.5、2 和 8 岁时的体重分别高出 22g（95%CI：8，37）、57g（95%CI：32，81）和 194g（95%CI：110，278），与低暴露组的同龄人相比。
在最高四分位组中产前暴露于丙烯酰胺的儿童在幼儿期体重增长速度略有增加，与最低四分位组的同龄人相比，超重/肥胖的患病率略有增加。我们的研究首次将产前丙烯酰胺暴露与产后生长联系起来。
